NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against NPS Pharmaceuticals, Inc. (“NPS” or the “Company”) (NASDAQ:NPSP) concerning the proposed acquisition of the Company by Shire plc (“Shire”) (LSE: SHP) (NASDAQ: SHPG). Under the terms of the merger agreement, NPS stockholders will receive $46.00 in cash for each share of NPS common stock they own, valuing the transaction at approximately $5.2 billion. The investigation concerns whether the NPS Board of Direct